Image guided radiotherapy: Current status of soft tissue imaging

Radiography ◽  
2014 ◽  
Vol 20 (2) ◽  
pp. 158-161 ◽  
Author(s):  
Helen A. McNair ◽  
Mark Elsworthy ◽  
June Dean ◽  
Charlotte Beardmore
2010 ◽  
Vol 10 (2) ◽  
pp. 121-136 ◽  
Author(s):  
Winky Wing Ki Fung ◽  
Vincent Wing Cheung Wu

AbstractThe sharp dose gradients in intensity-modulated radiation therapy increase the treatment sensitivity to various inter- and intra-fractional uncertainties, in which a slight anatomical change may greatly alter the actual dose delivered. Image-guided radiotherapy refers to the use of advanced imaging techniques to precisely track and correct these patient-specific variations in routine treatment. It can also monitor organ changes during a radiotherapy course. Currently, image-guided radiotherapy using computed tomography has gained much popularity in radiotherapy verification as it provides volumetric images with soft-tissue contrast for on-line tracking of tumour. This article reviews four types of computed tomography-based image guidance systems and their working principles. The system characteristics and clinical applications of the helical, megavoltage, computed tomography, and kilovoltage, cone-beam, computed tomography systems are discussed, given that they are currently the most commonly used systems for radiotherapy verification. This article also focuses on the recent techniques of soft-tissue contrast enhancement, digital tomosynthesis, four-dimensional fluoroscopic image guidance, and kilovoltage/megavoltage, in-line cone-beam imaging. These evolving systems are expected to take over the conventional two-dimensional verification system in the near future and provide the basis for implementing adaptive radiotherapy.


Author(s):  
Dian Wang ◽  
Ross A. Abrams

Radiotherapy for soft tissue sarcoma (STS) has advanced significantly over the past 50 years. This review focuses briefly on the period from 1964 to 1999 and more substantially on the changes of the past 15 years, such as IMRT and image-guided radiotherapy (IG-RT), especially when brought together (IG-IMRT) in the same planning and delivery process to treat localized STS. In particular, the introduction of IG-RT, target volume definitions for IG-RT, and review of recent clinical trials using IG-RT to treat localized STS in extremity will be reviewed. Finally, potential investigational agents combined with IG-RT to improve outcomes in patients with localized STS are discussed.


2011 ◽  
Vol 38 (6Part32) ◽  
pp. 3813-3813
Author(s):  
S Meer ◽  
E Bloemen ◽  
J Hermans ◽  
R Voncken ◽  
D Heuvelmans ◽  
...  

2010 ◽  
Vol 6 (3) ◽  
pp. 207-213 ◽  
Author(s):  
Julie A. Bradley ◽  
Kristofer Kainz ◽  
X. Allen Li ◽  
Dian Wang

2004 ◽  
Vol 31 (5) ◽  
pp. 1083-1092 ◽  
Author(s):  
William C. Lavely ◽  
Christopher Scarfone ◽  
Hakan Cevikalp ◽  
Rui Li ◽  
Daniel W. Byrne ◽  
...  

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Stefanie Corradini ◽  
Maximilian Niyazi ◽  
Dirk Verellen ◽  
Vincenzo Valentini ◽  
Seán Walsh ◽  
...  

AbstractFuture radiation oncology encompasses a broad spectrum of topics ranging from modern clinical trial design to treatment and imaging technology and biology. In more detail, the application of hybrid MRI devices in modern image-guided radiotherapy; the emerging field of radiomics; the role of molecular imaging using positron emission tomography and its integration into clinical routine; radiation biology with its future perspectives, the role of molecular signatures in prognostic modelling; as well as special treatment modalities such as brachytherapy or proton beam therapy are areas of rapid development. More clinically, radiation oncology will certainly find an important role in the management of oligometastasis. The treatment spectrum will also be widened by the rational integration of modern systemic targeted or immune therapies into multimodal treatment strategies. All these developments will require a concise rethinking of clinical trial design. This article reviews the current status and the potential developments in the field of radiation oncology as discussed by a panel of European and international experts sharing their vision during the “X-Change” symposium, held in July 2019 in Munich (Germany).


Sign in / Sign up

Export Citation Format

Share Document